- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05287945
Studie av orellanin vid metastaserande klarcellig eller papillär njurcellscancer
En fas I/II, öppen, enkelarmsstudie om säkerhet, tolerabilitet och antitumöreffektivitet av orellaninbehandling hos patienter med metastaserande klarcellig eller papillär njurcellscancer
A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma who have failed standard-of-care therapy. All participants must have end-stage kidney disease and be receiving stable chronic hemodialysis.
Studieöversikt
Detaljerad beskrivning
This is an open, non-controlled, phase I/II study evaluating the safety, tolerability, and anti-tumor efficacy of orellanine treatment in patients with metastatic clear-cell or papillary renal carcinoma. The study will include up to 75 patients and is conducted in 3 parts. The study will consist of 3 parts: Part A - an intra-patient dose escalation part, followed by a dose exposure (Part B), followed by a dose expansion (Part C).
Part A, which is now closed, used an intra patient dose escalation design to evaluate safety across multiple dose levels.
The study is currently in Part B, an exposure based dose escalation phase. Patients may be enrolled into either a 24 hour or a 72 hour exposure cohort. Exposure duration is defined by the timing of hemodialysis, as elimination of orellanine occurs primarily through dialysis initiated after infusion. The starting dose for Part B is 0.38 mg/kg, and the total dose per treatment cycle is limited to 2.5 mg/kg, including any replacement doses. A minimum of three patients will be enrolled in each cohort, and escalation to longer exposure durations occurs only after safety evaluation.
Part C is a planned dose expansion phase to further characterize safety and explore preliminary antitumor activity at the selected dose and exposure level.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Hanjing Xie, Ph.D.
- Telefonnummer: +46737031615
- E-post: hanjing.xie@oncorena.com
Studera Kontakt Backup
- Namn: Oncorena Study General Inquiries
- E-post: oncorella1@oncorena.com
Studieorter
-
-
-
Villejuif, Frankrike, 94805
- Rekrytering
- Institut de Cancerologie Gustave-Roussy
-
Kontakt:
- Christophe Massard, M.D., Ph.D
- Telefonnummer: +33142114211
- E-post: Christophe.massard@gustaveroussy.fr
-
Huvudutredare:
- Christophe Massard, M.D., Ph.D.
-
-
-
-
California
-
Orange, California, Förenta staterna, 92868
- Rekrytering
- University of California Irvine
-
Kontakt:
- Nataliya Mar, M.D.
- Telefonnummer: 714-456-5153
- E-post: marn@hs.uci.edu
-
Huvudutredare:
- Nataliya Mar, M.D.
-
Palo Alto, California, Förenta staterna, 94304
- Rekrytering
- Stanford
-
Kontakt:
- Sandhya Srinivas, M.D.
- Telefonnummer: 650-498-6000
- E-post: sandysri@stanford.edu
-
Huvudutredare:
- Sandhya Srinivas, MD
-
San Francisco, California, Förenta staterna, 94158
- Rekrytering
- University of California San Francisco
-
Kontakt:
- Arpita Desai, M.D.
- Telefonnummer: 415-476-4616
- E-post: arpita.desai@ucsf.edu
-
Huvudutredare:
- Arpita Desai, M.D.
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63130
- Rekrytering
- Washington University in St. Louis
-
Huvudutredare:
- Melissa Reimers, MD
-
Kontakt:
- Melissa Reimers, M.D.
- Telefonnummer: 314-273-3713
- E-post: mreimers@wustl.edu
-
-
New York
-
Buffalo, New York, Förenta staterna, 14263
- Rekrytering
- Roswell Park Comprehensive
-
Huvudutredare:
- Saby George, MD
-
Kontakt:
- Telefonnummer: 8313 M.D. 716-845-2300
- E-post: Saby.George@roswellpark.org
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Rekrytering
- University of Texas - MD Anderson Cancer Center
-
Kontakt:
- Nizar Tannir, M.D.
- Telefonnummer: 713-563-7265
- E-post: ntannir@mdanderson.org
-
Huvudutredare:
- Nizar Tannir, M.D.
-
-
-
-
-
Lisbon, Portugal, 1649-035
- Rekrytering
- START Lisbon - Hospital de Santa Maria Av
-
Kontakt:
- Andre Mansinho, M.D.
- Telefonnummer: +351 210 405 907
- E-post: andre.mansinho@startlisbon.com
-
Huvudutredare:
- Andre Mansinho, M.D.
-
-
-
-
-
Lleida, Spanien, 25004
- Rekrytering
- Clinica Mi Nova Alianca
-
Kontakt:
- Santiago Viteri, M.D., Ph.D.
- Telefonnummer: + 34 932287445
- E-post: santiago.viteri@pratia.com
-
Huvudutredare:
- Santiago Viteri, M.D.
-
-
-
-
-
Stockholm, Sverige
- Rekrytering
- Karolinska University Hospital
-
Huvudutredare:
- Jeffrey Yachnin
-
Kontakt:
- Jeffrey Yachnin
- Telefonnummer: +46812370000
- E-post: jeffrey.yachnin@regionstockholm.se
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion criteria:
-
Has provided written informed consent.
-
Has a diagnosis of histologically confirmed advanced ccRCC or pRCC. No conventional therapy is available or considered appropriate by the treating physician or is declined by the patient.
-
For patients in the expansion portion of the study only: Measurable disease per RECIST version 1.1 criteria.
-
ECOG performance status of 0 - 2.
-
Age ≥18 years.
-
Life expectancy ≥3 months.
-
Has acceptable haematologic laboratory values defined as:
- Neutrophils ≥1.5 × 10^9/L, without growth factor stimulation within 3 weeks prior to the blood test;
- Platelets ≥100 × 10^9/L;
- Haemoglobin ≥5.6 mmol/L (~90 g/L). Use of erythropoietin or blood transfusions are permitted.
-
Has acceptable liver laboratory values defined as:
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN (≤5 × ULN for patients with liver metastases
- Total bilirubin ≤1.5 × ULN or direct bilirubin ≤ ULN for patients with total bilirubin levels >1.5 × ULN
- For patients diagnosed with Gilbert's syndrome, total bilirubin ≤2 × ULN is acceptable.
-
Must be on chronic hemodialysis (on a consistent regimen for the previous three months, with allowance for intermittent treatments as required for volume overload).
-
The patient's treating nephrologist and oncologist agree that the prospect of loss of remaining renal function resulting from this treatment will not significantly change the patient's future and chronic dialysis treatment.
-
Female patients of child-bearing potential and male patients must agree to use 2 forms of highly effective contraception for the duration of study treatment and after the last dose of orellanine for at least 3 months for males and 6 months for females.
-
For females of child-bearing potential, a negative serum pregnancy test at screening.
-
Patients who are willing and able to comply with travel requirements, scheduled visits, treatment schedule, efficacy assessments, laboratory tests, and other study procedures.
Exclusion criteria:
- Diagnosis of any other malignancy within 2 years prior to enrolment, except for adequately treated basal cell or squamous cell skin cancer, superficial melanoma, or carcinoma in situ of the breast or of the cervix, or low grade (Gleason 7 or below) prostate cancer on surveillance with no plans for treatment intervention (e.g., surgery, radiation, or castration)
- Radiotherapy within 2 weeks before first dose.
- Immuno-oncology therapy (IO) given in the last six (6) months prior to enrolment
- Other systemic anti-cancer therapy within 2 weeks before first dose.
- Has not recovered from AEs due to prior anti-cancer medications to at least grade 1 by CTCAE version 5.0 (except for alopecia and grade 2 neuropathy).
- Has received any other investigational product within 4 weeks before first dose.
- Pregnant or breastfeeding women.
- Uncontrolled medical condition including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements, or would, in the opinion of the investigator, place the patient at increased risk.
- QTc interval at baseline of ≥470 msec.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Part B - 24-Hour Exposure Cohort
Participants receive orellanine (ONC175) as a 30 minute intravenous infusion once during each 28 day treatment cycle. Hemodialysis is performed the day before the infusion and again approximately 24 hours after the infusion to define the exposure period, as orellanine is eliminated primarily through dialysis. Participants will continue their regular hemodialysis schedule throughout the cycle. |
Orellanine administered intravenously |
|
Experimentell: Part B - 72 Hour Exposure Cohort
Participants receive orellanine (ONC175) as a 30 minute intravenous infusion once during each 28 day treatment cycle. In this cohort, hemodialysis is performed on the morning of the infusion, and additional hemodialysis sessions occur on the following days. Replacement doses of orellanine may be administered on the days after the initial infusion, depending on the assigned dose level. Hemodialysis is performed approximately 72 hours after the initial infusion to define the extended exposure period, as orellanine is eliminated primarily through dialysis. |
Orellanine administered intravenously |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Maximal tolererbar dos av orellanin
Tidsram: Genom avslutad studie ca 1 år
|
Genom avslutad studie ca 1 år
|
|
Biverkningar och laboratorieavvikelser enligt NCI CTCAE v5.0.
Tidsram: Genom avslutad studie ca 1 år
|
Genom avslutad studie ca 1 år
|
|
Förändringar i arteriella blodtrycksmätningar
Tidsram: Genom avslutad studie ca 1 år
|
Genom avslutad studie ca 1 år
|
|
Förändringar i pulsmätningar
Tidsram: Genom avslutad studie ca 1 år
|
Genom avslutad studie ca 1 år
|
|
Förändringar i andningsfrekvensmätningar
Tidsram: Genom avslutad studie ca 1 år
|
Genom avslutad studie ca 1 år
|
|
Förändringar i temperaturmätningar
Tidsram: Genom avslutad studie ca 1 år
|
Genom avslutad studie ca 1 år
|
|
Förändringar i fysiska undersökningsfynd
Tidsram: Genom avslutad studie ca 1 år
|
Genom avslutad studie ca 1 år
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Effekten av orellanin baserat på tid till tumörsvar
Tidsram: Genom avslutad studie ca 1 år.
|
Genom avslutad studie ca 1 år.
|
|
Effekten av orellanin baserat på bästa totala svar
Tidsram: Genom avslutad studie ca 1 år.
|
Genom avslutad studie ca 1 år.
|
|
Area under kurvan extrapolerad till oändlighet
Tidsram: Genom avslutad studie ca 1 år.
|
Genom avslutad studie ca 1 år.
|
|
Delområde under kurvan
Tidsram: Genom avslutad studie ca 1 år.
|
Genom avslutad studie ca 1 år.
|
|
Dosproportionalitet
Tidsram: Genom avslutad studie ca 1 år.
|
Genom avslutad studie ca 1 år.
|
|
Tid till maximal plasmakoncentration
Tidsram: Genom avslutad studie ca 1 år.
|
Genom avslutad studie ca 1 år.
|
|
Maximal plasmakoncentration
Tidsram: Genom avslutad studie ca 1 år.
|
Genom avslutad studie ca 1 år.
|
|
Totalt kroppsavstånd
Tidsram: Genom avslutad studie ca 1 år.
|
Genom avslutad studie ca 1 år.
|
|
Distributionsvolym
Tidsram: Genom avslutad studie ca 1 år.
|
Genom avslutad studie ca 1 år.
|
|
Terminal halveringstid
Tidsram: Genom avslutad studie ca 1 år.
|
Genom avslutad studie ca 1 år.
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Allmänna publikationer
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
- Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. No abstract available.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
- Buvall L, Hedman H, Khramova A, Najar D, Bergwall L, Ebefors K, Sihlbom C, Lundstam S, Herrmann A, Wallentin H, Roos E, Nilsson UA, Johansson M, Tornell J, Haraldsson B, Nystrom J. Orellanine specifically targets renal clear cell carcinoma. Oncotarget. 2017 Jul 25;8(53):91085-91098. doi: 10.18632/oncotarget.19555. eCollection 2017 Oct 31.
- Dy GW, Gore JL, Forouzanfar MH, Naghavi M, Fitzmaurice C. Global Burden of Urologic Cancers, 1990-2013. Eur Urol. 2017 Mar;71(3):437-446. doi: 10.1016/j.eururo.2016.10.008. Epub 2016 Oct 28.
- Hedman H, Holmdahl J, Molne J, Ebefors K, Haraldsson B, Nystrom J. Long-term clinical outcome for patients poisoned by the fungal nephrotoxin orellanine. BMC Nephrol. 2017 Apr 3;18(1):121. doi: 10.1186/s12882-017-0533-6.
- Merza H, Bilusic M. Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. Curr Oncol Rep. 2017 Apr;19(4):27. doi: 10.1007/s11912-017-0583-8.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Patologiska processer
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Neoplasmer
- Manliga urogenitala sjukdomar
- Njursjukdomar
- Urologiska sjukdomar
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Kronisk sjukdom
- Sjukdomsegenskaper
- Neoplasmer efter histologisk typ
- Neoplasmer, körtel och epitel
- Adenocarcinom
- Neoplastiska processer
- Njurinsufficiens
- Urologiska neoplasmer
- Carcinom
- Njurinsufficiens, kronisk
- Patologiska tillstånd, tecken och symtom
- Neoplasma Metastas
- Karcinom, njurcell
- Njursvikt, kronisk
- Neoplasmer i njurarna
- orellanin
Andra studie-ID-nummer
- ONC001-CL-001
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Pursuant to relevant data protection and privacy legislation, patients will authorize the collection, use and disclosure of their study data by the investigator and by those persons who need that information for the purposes of the study.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .